Currently, BCSCs are usually identified by expression of specific phenotypes; CD44+/CD24−/low and/or CD133+ are most frequently used (Li et al., 2017), and it is identified as a small subpopulation of heterogeneous breast cancer cells with strong self-renewal and proliferation properties (Zhang et al., 2020). This evidence concerns the gene CD44 and breast cancer.